Últimas noticias sobre Portage Biotech (NASDAQ:PRTG) Bolsa

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Portage Biotech Inc

On March 27, Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google introduced several new features across <a target="_blank" href="https://www.benzinga.com/topic/google" rel="noreferrer noopener">Search, Maps, and Gemini</a> to enhance vacation planning, BofA Securities noted Monday.
In Search, users can generate detailed travel itineraries with AI Overviews, which can be saved as custom lists in Google Maps.
Google has also expanded hotel price tracking globally, letting users know when rates change.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43127416/anthropic-gains-big-with-google-backing-aiming-for-60-billion-valuation-and-surging-ai-revenue" rel="noreferrer noopener">Anthropic Gains Big With Google Backing, Aims for $60 Billion Valuation and Surging AI Revenue</a>
A new screenshot-powered feature on Google Maps uses Gemini AI to identify places saved through screenshots, enabling users to organize and visualize their travel ideas.
Additionally, Google has made Gemini&#8217;s Gems feature available to all users for free. Gems allows users to create personalized AI assistants tailored to specific tasks within Gemini.
Travel is a critical vertical for Google, as it drives high-intent searches across hotels and flights, implying categories with strong monetization.
The new AI features can drive incremental queries on Google&#8217;s platform by engaging users earlier in decision-making.
The analyst noted that rather than transactional keywords like &#8220;cheap flights to Paris,&#8221; users can ask broader questions such as &#8220;suggest scenic road trip routes in California.&#8221; This will extend the volume and diversity of search queries, allowing Google to deliver more relevant results and target more high-value commercial content.
The analyst noted that the integrations also improve Google&#8217;s ability to compete with emerging AI search platforms (such as ChatGPT and Perplexity), which have been improving travel planning capabilities.
Perplexity has partnered with Selfbook and TripAdvisor, Inc to enable users to book hotel reservations. The booking tool could have discounts for Pro users, and the company has suggested air and rental car booking tools could follow. TripAdvisor will provide information on reviews and experiences to help travelers make choices.
The analyst noted that AI companies are, again, partnering with travel aggregators over suppliers OTAs (Online Travel Agencies) (Expedia Group, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/expe#NASDAQ">EXPE</a>) at 3 million) but are looking to expand rapidly.
The analyst said Gemini could partner with OTAs if the company pursues agentic AI tools this year. Google&#8217;s itinerary creation capabilities and Perplexity&#8217;s AI booking tools will also be built and offered by OTAs (including Booking and Expedia).
The OTAs can leverage their travel and customer data to offer competitive AI services, while their loyalty programs (unique discounts and points) could be competitive advantages.
For Airbnb, Inc., the company must best leverage its unique proprietary inventory, a key asset in an evolving AI world.
Price Action: GOOGL stock is down 0.64% at $153.34 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43165472/samsung-taps-google-ai-qualcomm-tech-for-galaxy-s25-to-rival-apples-iphone" target="_blank" rel="noreferrer noopener">Samsung Taps Google AI, Qualcomm Tech for Galaxy S25 to Rival Apple&#8217;s iPhone</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Travel

Analyst Ratings

General

EXPE

GOOG

GOOGL

Google's New AI Travel Features Could Drive Major Growth In Search Volume: Analyst

The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinzi&nbsp;(durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi&nbsp;as adjuvant monotherapy&nbsp;after radical cystectomy (surgery to remove the bladder) for adult patients with muscle-<a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">invasive bladder cancer (MIBC)</a>.
The FDA approval was based on results from the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44558058/imfinzi-durvalumab-approved-in-the-us-as-first-and-only-perioperative-immunotherapy-for-patients-w" rel="noreferrer noopener">NIAGARA Phase 3 trial</a>.
In a planned interim analysis, the Imfinzi-based&nbsp;perioperative regimen demonstrated a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus the comparator arm.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44188407/astrazenecas-imfinzi-based-regimen-shows-improved-event-free-survival-in-early-stage-gastric-cancer-patients" rel="noreferrer noopener">AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients</a>
The estimated median event-free survival (EFS) has not yet been reached for the Imfinzi arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event-free at two years compared to 59.8% in the comparator arm.
Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus neoadjuvant chemotherapy with radical cystectomy.
Median survival was not yet reached for either arm. An estimated 82.2% of patients treated with the regimen were alive at two years compared to 75.2% in the comparator arm.
Concurrently, AstraZeneca's&nbsp;Calquence&nbsp;(acalabrutinib) in combination with bendamustine and rituximab was <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-recommended-for-eu-approval-in-1l-mcl.html" rel="noreferrer noopener">recommended</a> for approval in the European Union for adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous hematopoietic stem cell transplantation.
The positive opinion was based on the &nbsp;ECHO Phase 3 trial results.
Calquence&nbsp;plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy.
Median PFS was 66.4 months for patients treated with the Calquence combination versus 49.6 with chemoimmunotherapy alone.
Price Action: AZN stock is down 0.86% at $73.16 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44566612/palatin-technologies-obesity-drug-co-administered-with-eli-lillys-blockbuster-drug-shows-44-reduction-in-weight-vs-placebo" target="_blank" rel="noreferrer noopener">Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight</a></li>
</ul>
Image by Robert Way via Shutterstock

Biotech

Large Cap

Health Care

FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients

Investors with a lot of money to spend have taken a bearish stance on Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ENPH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Enphase Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 27% bullish and 54%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $722,785, and 4 are calls, for a total amount of $120,244.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $80.0 for Enphase Energy during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Enphase Energy's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Enphase Energy's substantial trades, within a strike price spectrum from $35.0 to $80.0 over the preceding 30 days.
<h3>Enphase Energy Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743445845_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.35</td>
<td>$2.74</td>
<td>$4.2</td>
<td>$55.00</td>
<td>$420.0K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.3</td>
<td>$20.65</td>
<td>$20.81</td>
<td>$80.00</td>
<td>$104.0K</td>
<td>750</td>
<td>50</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$12.9</td>
<td>$12.35</td>
<td>$12.35</td>
<td>$70.00</td>
<td>$74.1K</td>
<td>733</td>
<td>61</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.5</td>
<td>$20.7</td>
<td>$21.35</td>
<td>$75.00</td>
<td>$38.4K</td>
<td>2.8K</td>
<td>18</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.96</td>
<td>$1.81</td>
<td>$1.88</td>
<td>$80.00</td>
<td>$37.6K</td>
<td>1.5K</td>
<td>255</td>
</tr>
</tbody>
</table>

<h3>About Enphase Energy</h3>
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Following our analysis of the options activities associated with Enphase Energy, we pivot to a closer look at the company's own performance.
<h3>Enphase Energy's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,486,838, the ENPH's price is down by -0.63%, now at $61.26. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 22 days.</li>
</ul>
<h3>What Analysts Are Saying About Enphase Energy</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $75.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Enphase Energy, targeting a price of $75. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Enphase Energy with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

ENPH

Enphase Energy Options Trading: A Deep Dive into Market Sentiment

Deep-pocketed investors have adopted a bullish approach towards Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SHEL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Shell. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 44% bearish. Among these notable options, 4 are puts, totaling $245,090, and 5 are calls, amounting to $675,266.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $80.0 for Shell over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Shell's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Shell's significant trades, within a strike price range of $70.0 to $80.0, over the past month.
<h3>Shell 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743445840_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$70.00</td>
<td>$270.0K</td>
<td>18.2K</td>
<td>1.5K</td>
</tr>
<tr>
<td>SHEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$70.00</td>
<td>$265.7K</td>
<td>18.2K</td>
<td>751</td>
</tr>
<tr>
<td>SHEL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.5</td>
<td>$2.45</td>
<td>$2.45</td>
<td>$72.50</td>
<td>$78.8K</td>
<td>733</td>
<td>8</td>
</tr>
<tr>
<td>SHEL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$75.00</td>
<td>$64.3K</td>
<td>403</td>
<td>226</td>
</tr>
<tr>
<td>SHEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$75.00</td>
<td>$60.8K</td>
<td>466</td>
<td>179</td>
</tr>
</tbody>
</table>

<h3>About Shell</h3>
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.5 million barrels of liquids and 7.3 billion cubic feet of natural gas per day. At end-2023, reserves stood at 9.6 billion barrels of oil equivalent, 49% of which, consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.6 mmb/d located in the Americas, Asia, Africa, and Europe and sells about 12 million tons per year of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Following our analysis of the options activities associated with Shell, we pivot to a closer look at the company's own performance.
<h3>Current Position of Shell</h3>
<ul>
<li>Trading volume stands at 4,275,657, with SHEL's price up by 0.35%, positioned at $72.98.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 32 days.</li>
</ul>
<h3>Professional Analyst Ratings for Shell</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $84.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from TD Securities continues to hold a Buy rating for Shell, targeting a price of $82. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Shell, targeting a price of $87. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Shell options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

SHEL

Shell Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 30 are puts, for a total amount of $1,594,617 and 8, calls, for a total amount of $394,717.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.5 to $60.0 for Moderna over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $22.5 to $60.0 over the preceding 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743445834_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$33.15</td>
<td>$33.15</td>
<td>$33.15</td>
<td>$60.00</td>
<td>$198.9K</td>
<td>215</td>
<td align="right">49</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.3</td>
<td>$6.15</td>
<td>$6.3</td>
<td>$30.00</td>
<td>$126.0K</td>
<td>1.0K</td>
<td align="right">215</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$8.45</td>
<td>$7.45</td>
<td>$8.45</td>
<td>$30.00</td>
<td>$114.0K</td>
<td>195</td>
<td align="right">228</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.45</td>
<td>$14.65</td>
<td>$14.65</td>
<td>$40.00</td>
<td>$84.9K</td>
<td>6.4K</td>
<td align="right">119</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$31.00</td>
<td>$83.3K</td>
<td>258</td>
<td align="right">199</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 15,324,366, the MRNA's price is down by -8.44%, now at $28.5. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 31 days.</li>
</ul>
<h3>Expert Opinions on Moderna</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $36.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $33. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $40.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

MRNA

Moderna's Options Frenzy: What You Need to Know

Jefferies analyst Sheila Kahyaoglu maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Buy and lowers the price target from $260 to $250.

Price Target

Jefferies Maintains Buy on L3Harris Technologies, Lowers Price Target to $250

Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares are trading lower Monday, potentially after the company announced it is spinning off its Bitcoin mining operations into a new entity, American Bitcoin, <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44560290/trump-family-to-dive-into-bitcoin-mining-after-defi-meme-coin-projects">in partnership with Eric Trump</a>.
What To Know: Hut 8 transferred most of its ASIC miners to American Bitcoin in exchange for an 80% stake. The new company aims to become the largest Bitcoin miner with a target of 50+ exahashes per second and plans to build a strategic Bitcoin reserve. It also intends to go public.
American Bitcoin will operate under Hut 8's Compute segment, but Hut 8 will manage its infrastructure and operations under long-term agreements. This allows Hut 8 to focus on infrastructure while American Bitcoin handles mining.
The leadership team includes Mike Ho as Executive Chairman, Matt Prusak as CEO and Eric Trump as Chief Strategy Officer. The board includes Ho, Hut 8 CEO Asher Genoot, Justin Mateen and Michael Broukhim.
Eric Trump and Donald Trump Jr. said the deal supports Bitcoin and decentralized finance. Hut 8's CEO said the spin-off allows each business to raise capital separately.
Price Action: Hut 8 shares are down 0.81% at $11.63 at the time of writing, according to Benzinga Pro.
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31141848/Screenshot-2025-03-31-at-14.18.21-1024x504.png" alt="" class="wp-image-849783" style="width:435px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31141848/Screenshot-2025-03-31-at-14.18.21-1024x504.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31141848/Screenshot-2025-03-31-at-14.18.21-300x148.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31141848/Screenshot-2025-03-31-at-14.18.21-768x378.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31141848/Screenshot-2025-03-31-at-14.18.21.png 1511w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44567164/circle-eyes-5-billion-valuation-for-upcoming-initial-public-offering">Circle Eyes $5 Billion Valuation For Upcoming Initial Public Offering</a></li>
</ul>
Image Via Shutterstock.

Movers

Hut 8 Shares Are Down Today: What's Going On?

Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) announced on Monday that <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44560854/powered-by-5th-gen-amd-epyc-cpus-oracle-cloud-infrastructure-compute-e6-shapes-deliver-breakthroug" rel="noreferrer noopener">fifth-generation AMD EPYC processors</a> power the Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) Oracle Cloud Infrastructure (OCI) Compute E6 Standard shapes.
The fifth&nbsp;generation AMD EPYC processors, the world&#8217;s best server CPUs for enterprise, AI, and cloud, enable OCI Compute E6 shapes to deliver up to a 2 times increase in cost to performance, compared to the previous E5 instance generation based on testing by OCI.
The new OCI Compute E6 shapes build on the success of the previous E5 generation to deliver leadership performance and cost efficiency for general-purpose and compute-intensive workloads.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43788975/amd-closing-competitive-gpu-gap-with-nvidia-gains-market-share-from-intel-in-client-and-server-markets-analyst" rel="noreferrer noopener">AMD Closing Competitive GPU Gap With Nvidia, Gains Market Share From Intel In Client And Server Markets: Analyst</a>
AMD senior vice president and general manager Dan McNamara noted the combination of OCI&#8217;s flexible infrastructure and the performance of fifth&nbsp;Gen AMD EPYC processors helps customers accelerate their most demanding workloads while optimizing their cloud infrastructure.
OCI Compute E6 Standard bare metal instances and virtual machines are available in regions, including the US East (Ashburn), US West (Phoenix), US Midwest (Chicago), Germany Central (Frankfurt), and UK South (London). A rollout is planned for additional regions in the coming months.
AMD stock plunged 45% in the last 12 months.
In March, Jefferies analyst&nbsp;Blayne Curtis <a target="_blank" href="https://www.benzinga.com/25/03/44511459/amd-stock-falls-nearly-3-in-thursday-pre-market-whats-going-on" rel="noreferrer noopener">downgraded the stock</a> to Hold from Buy and lowered its price target from $135 to $120. Curtis&nbsp;identified the increasing rivalry from&nbsp;Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). A Jefferies benchmarking study showed AMD&#8217;s graphics processing units being significantly outpaced by those of&nbsp;Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
in various open-source models.
AMD is under pressure as the US tightens export controls on Chinese firms. The Commerce Department blacklisted over 50 Chinese entities, limiting their access to advanced semiconductors from AMD, affecting its China revenue.
Price Action: AMD stock is down 1.37% at $101.81 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/03/44563420/despite-us-expansion-taiwan-semiconductor-reaffirms-commitment-to-home-base-with-new-initiatives-reuters" target="_blank" rel="noreferrer noopener">Despite US Expansion, Taiwan Semiconductor Reaffirms Commitment To Home Base With New Initiatives: Reuters</a></li>
</ul>
Photo Via AMD

Tech

INTC

NVDA

ORCL

AMD Powers Oracle Cloud With New Epyc Chips Promising Major Boost In Performance

NLS Pharmaceutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) shares are trading higher on Monday after the company announced it secured up to $2 million in equity financing, with a possibility of an additional $1 million, or <a href="https://www.benzinga.com//node/44561503">$1.65 per share</a>.
What To Know: In addition to the $3 million financing agreement, NLS also signed a $25 million committed equity facility agreement. Both funding agreements are intended to support the merger between NLS and Kadimastem.
Specifically, the funding will support Kadimastem&#8217;s Phase IIa multi-site clinical trial for Amyotrophic Lateral Sclerosis using AstroRx and Phase I trial for IsletRx in type 1 diabetes patients.
&#8220;We are pleased to have secured this capital on favorable terms, which reflects investor confidence in our vision and the transformative potential of our planned merger with Kadimastem,&#8221; said Alex Zwyer, CEO of NLS. 
&#8220;We believe that with these financial resources in place, we are well-positioned to move forward with completing the transaction and creating a leading company in the field of regenerative medicine and CNS disorders.&#8221;
See Also: <a href="https://www.benzinga.com/25/03/44566612/palatin-technologies-obesity-drug-co-administered-with-eli-lillys-blockbuster-drug-shows-44-reduction-in-weight-v">Palatin Technologies&#8217; Obesity Drug Co-Administered With Eli Lilly&#8217;s Blockbuster Drug Shows 4.4% Reduction In Weight</a>
NLSP Price Action: At the time of writing, NLS Pharmaceutics stock is trading 13.1% higher at $1.47, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

NLSP

What's Going On With NLS Pharmaceutics Shares Monday?

<a href="https://www.foxbusiness.com/video/6370703853112" title="https://www.foxbusiness.com/video/6370703853112">https://www.foxbusiness.com/video/6370703853112</a>

LCID

TSLA

Lucid CEO Says We Are Seeing An Uptick In Orders From Former Tesla Owners- Fox Business Interview

Jefferies analyst Andrew Uerkwitz maintains Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Hold and lowers the price target from $28 to $24.

Jefferies Maintains Hold on Unity Software, Lowers Price Target to $24

Jefferies analyst Joseph Gallo maintains Radware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDWR#NASDAQ">RDWR</a>) with a Hold and lowers the price target from $26 to $24.

RDWR

Jefferies Maintains Hold on Radware, Lowers Price Target to $24

Contracts

L3Harris, Dutch Ministry Of Defence Sign FOXTROT Long-Term Agreement For Up To €1B

Jefferies analyst Joseph Gallo maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Hold and lowers the price target from $145 to $130.

QLYS

Jefferies Maintains Hold on Qualys, Lowers Price Target to $130

WIIM

SHOT

Safety Shot shares are trading lower after the company CEO provided a business update.

VIGL

Vigil Neuroscience shares are trading lower. The company announced it filed a prospectus regarding a stock offering to sell 5.38 million shares from an existing stockholder.

Jefferies analyst Joseph Gallo maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Hold and lowers the price target from $45 to $37.

TENB

Jefferies Maintains Hold on Tenable Holdings, Lowers Price Target to $37

Whales with a lot of money to spend have taken a noticeably bullish stance on United Parcel Service.
Looking at options history for United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) we detected 24 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $557,490 and 13, calls, for a total amount of $1,510,948.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $90.0 and $150.0 for United Parcel Service, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for United Parcel Service's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Parcel Service's whale activity within a strike price range from $90.0 to $150.0 in the last 30 days. 
<h3>United Parcel Service 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743444952_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$9.35</td>
<td>$8.9</td>
<td>$8.9</td>
<td>$125.00</td>
<td>$371.1K</td>
<td>1.0K</td>
<td>451</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.65</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$135.00</td>
<td>$304.8K</td>
<td>1.4K</td>
<td>499</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.35</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$115.00</td>
<td>$162.5K</td>
<td>7.0K</td>
<td>768</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.25</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$115.00</td>
<td>$160.0K</td>
<td>7.0K</td>
<td>1.2K</td>
</tr>
<tr>
<td>UPS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$25.4</td>
<td>$25.05</td>
<td>$25.05</td>
<td>$90.00</td>
<td>$125.2K</td>
<td>94</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About United Parcel Service</h3>
As the world's largest parcel delivery company, UPS manages a massive fleet of more than 500 planes and 100,000 vehicles, along with many hundreds of sorting facilities, to deliver an average of about 22 million packages per day to residences and businesses across the globe. UPS' domestic US package operations generate around 65% of total revenue while international package makes up 20%. Air and ocean freight forwarding and contract logistics make up the remainder.
Having examined the options trading patterns of United Parcel Service, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of United Parcel Service</h3>
<ul>
<li>With a trading volume of 2,291,605, the price of UPS is down by -0.88%, reaching $108.7.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>What Analysts Are Saying About United Parcel Service</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $119.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on United Parcel Service with a target price of $120. 
&#x2A; Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $140. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Underweight rating on United Parcel Service with a target price of $90. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for United Parcel Service, targeting a price of $129. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for United Parcel Service with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On United Parcel Service

Benzinga's options scanner has just identified more than 8 option transactions on Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), with a cumulative value of $959,910. Concurrently, our algorithms picked up 3 puts, worth a total of 745,410.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $110.0 for Cava Group, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cava Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cava Group's significant trades, within a strike price range of $60.0 to $110.0, over the past month.
<h3>Cava Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743444947_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.95</td>
<td>$8.7</td>
<td>$9.5</td>
<td>$110.00</td>
<td>$1.9M</td>
<td align="right">464</td>
<td>2.0K</td>
</tr>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$1.01</td>
<td>$0.67</td>
<td>$0.73</td>
<td>$65.00</td>
<td>$688.8K</td>
<td align="right">0</td>
<td>8.9K</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$33.0</td>
<td>$32.4</td>
<td>$33.0</td>
<td>$60.00</td>
<td>$99.0K</td>
<td align="right">730</td>
<td>33</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.93</td>
<td>$1.43</td>
<td>$1.79</td>
<td>$91.00</td>
<td>$44.7K</td>
<td align="right">360</td>
<td>253</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.85</td>
<td>$7.6</td>
<td>$7.75</td>
<td>$85.00</td>
<td>$38.7K</td>
<td align="right">497</td>
<td>102</td>
</tr>
</tbody>
</table>

<h3>About Cava Group</h3>
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
Following our analysis of the options activities associated with Cava Group, we pivot to a closer look at the company's own performance.
<h3>Cava Group's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,596,501, the price of CAVA is down by 0.0%, reaching $85.85.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 57 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cava Group</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $111.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from B of A Securities lowers its rating to Buy with a new price target of $112. 
&#x2A; An analyst from JP Morgan has elevated its stance to Overweight, setting a new price target at $110. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cava Group, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

CAVA

Cava Group Options Trading: A Deep Dive into Market Sentiment

Investors with significant funds have taken a bullish position in UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in TIGR usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 41 options transactions for UP Fintech Holding. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 85% being bullish and 12% bearish. Of all the options we discovered, 40 are puts, valued at $4,352,142, and there was a single call, worth $169,974.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $8.0 to $9.0 for UP Fintech Holding over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for UP Fintech Holding options trades today is 11084.25 with a total volume of 480,126.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for UP Fintech Holding's big money trades within a strike price range of $8.0 to $9.0 over the last 30 days.
<h3>UP Fintech Holding Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743444942_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIGR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$1.49</td>
<td>$1.45</td>
<td>$1.45</td>
<td>$8.00</td>
<td>$435.3K</td>
<td>444</td>
<td>7.3K</td>
</tr>
<tr>
<td>TIGR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$1.49</td>
<td>$1.44</td>
<td>$1.44</td>
<td>$8.00</td>
<td>$288.2K</td>
<td>444</td>
<td>20.3K</td>
</tr>
<tr>
<td>TIGR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$1.43</td>
<td>$1.4</td>
<td>$1.4</td>
<td>$8.00</td>
<td>$183.9K</td>
<td>444</td>
<td>27.3K</td>
</tr>
<tr>
<td>TIGR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.04</td>
<td>$1.03</td>
<td>$1.04</td>
<td>$9.00</td>
<td>$173.4K</td>
<td>458</td>
<td>1.6K</td>
</tr>
<tr>
<td>TIGR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$1.36</td>
<td>$1.28</td>
<td>$1.34</td>
<td>$9.00</td>
<td>$169.9K</td>
<td>32.1K</td>
<td>701</td>
</tr>
</tbody>
</table>

<h3>About UP Fintech Holding</h3>
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
Having examined the options trading patterns of UP Fintech Holding, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of UP Fintech Holding</h3>
<ul>
<li>With a trading volume of 5,029,455, the price of TIGR is down by -3.56%, reaching $8.36.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What The Experts Say On UP Fintech Holding</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $9.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Citigroup has upgraded their rating to Neutral and adjusted the price target to $9. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UP Fintech Holding with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

TIGR

UP Fintech Holding Unusual Options Activity

Press Releases

"Stocks Under $1 Gaining Momentum: WBUY, KAVL, OMEX, PRTG, RJDG – Driving Innovation, Market Trends, and Growth Potential"

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Management

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Comments

Portage Biotech

Noticias

Últimas noticias sobre Portage Biotech (NASDAQ:PRTG) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL